Cannabinergic Nitrate Esters for Selective Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinergic compounds primarily act as mixed agonists at both CB1 and CB2 receptors, limiting their therapeutic specificity and efficacy for various medical conditions, particularly in pain management and weight regulation.
Innovation Solution
Development of novel cannabinergic nitrate esters and related analogs represented by general formulas I and II, which can bind covalently to CB1 and CB2 receptors, offering improved specificity and potency as CB1 agonists or antagonists, potentially enhancing antinociceptive effects and weight regulation mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If mixed agonist cannabinergic compounds are used at both CB1 and CB2 receptors, then broad therapeutic coverage is achieved, but therapeutic specificity and efficacy for particular medical conditions deteriorates
Solution Approach 1:
The patent segments the cannabinergic activity into separate compounds with selective receptor affinity. Instead of using mixed agonists that activate both CB1 and CB2 receptors simultaneously, the invention develops distinct compounds: one with selective CB1 agonist activity and another with selective CB2 agonist activity. This segmentation allows clinicians to choose the appropriate compound based on the specific medical condition, thereby improving therapeutic specificity while maintaining versatility through the availability of multiple specialized agents.
Solution Approach 2:
The patent inverts the conventional approach by developing compounds with selective receptor binding profiles rather than mixed agonist activity. Instead of starting with broad-spectrum cannabinergic compounds and attempting to enhance their efficacy, the invention reverses the strategy by creating highly selective CB1 and CB2 agonists that can be individually optimized for specific therapeutic indications, thus achieving both specificity and versatility.
2Reliability
If conventional cannabinergic compounds are used for pain management, then general analgesic effects are achieved, but targeted antinociceptive efficacy deteriorates
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures that confer selective affinity for either CB1 or CB2 receptors. The CB1-selective compound (Formula I) and CB2-selective compound (Formula II) have distinct structural characteristics that determine their local quality of receptor interaction. This enables targeted antinociceptive effects: CB1 compounds for central pain pathways and CB2 compounds for peripheral inflammatory pain, thereby achieving precise antinociceptive targeting while maintaining reliable analgesic effects.
3Adaptability or versatility
If non-selective cannabinergic agents are used for weight regulation, then general metabolic effects are achieved, but targeted therapeutic profile deteriorates
Solution Approach 1:
The patent segments cannabinergic metabolic effects into CB1-mediated and CB2-mediated pathways through the development of selective agonists. CB1-selective compounds can be used to target central appetite regulation and energy balance, while CB2-selective compounds can address peripheral metabolic processes and inflammation-related metabolic dysfunction. This segmentation enables tailored therapeutic profiles for weight regulation based on the specific metabolic disturbance, improving precision while maintaining versatility through mechanism-based treatment selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate enhanced antinociceptive effects and improved therapeutic profiles, providing more targeted approaches for pain management and weight regulation compared to existing cannabinergic agents.
Implementation Method 1
These compounds can bind covalently to CB1 and CB2 receptors
Data Source
AI summary
Biologically active cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools or biomarkers. Pharmaceutical compositions may include one or more of the nitrate ester compounds. Medicaments include one or more of the cannabinergic nitrate ester compounds and are useful in treating a variety of diseases. A method of treating, preventing or reducing the severity of a condition includes administering at least one of the disclosed nitrate ester compounds to an individual or animal in need thereof.